Low pre-treatment frequency of CD8+PD-1+CD73+ T cells in the peripheral blood of melanoma patients was associated with clinical benefit to nivolumab, indicating that, analysis of CD73 on circulating T cells at baseline may help to identify subsets of patients who most likely will benefit from nivolumab treatment. The gene discussed is PDCD1; the disease is melanoma.